TP53 and cancer: Furthermore, the immunotherapeutic resistance features of low PD-L1 related to TP53 mutations and cold immune microenvironmental profiles found in this study could aid in the development of optimized combination strategies, including chemo- and targeted therapies, to maximize the effects of cancer immunotherapy in HNSCC.